<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IPR-17013115</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-10-26</date_registration>
      <primary_sponsor>Huadong Hospital Affiliated to Fudan University</primary_sponsor>
      <public_title>Administration of Amifostine in the phase of induction remission alleviating complications in Auto-HSCT: A multi-center, open control and comparative study</public_title>
      <acronym />
      <scientific_title>Administration of Amifostine in the phase of induction remission alleviating complications in Auto-HSCT: A multi-center, open control and comparative study</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-02-01</date_enrolment>
      <type_enrolment />
      <target_size>Amifostine:100;Control:100;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=22290</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>Post-market</phase>
      <hc_freetext>Lymphoma</hc_freetext>
      <i_freetext>Amifostine:Amifostine will be routinely administrated in the phase of induction remission;Control:Amifostine will be only administrated in auto-HSCT;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Kefei Wu</firstname>
        <middlename />
        <lastname />
        <address>221 Yan'an Road West, Jing'an District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200032</zip>
        <telephone>+86 15121013309</telephone>
        <email>wkfwkfwkf@hotmail.com</email>
        <affiliation>Huadong Hospital Affiliated to Fudan University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Yanhui Xie</firstname>
        <middlename />
        <lastname />
        <address>221 Yan'an Road West, Jing'an District, Shanghai, China</address>
        <city />
        <country1 />
        <zip>200032</zip>
        <telephone>+86 13321957387</telephone>
        <email>yanhuixie@163.com</email>
        <affiliation>Huadong Hospital Affiliated to Fudan University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. All the patients should be diagnosed with lymphoma which is verified by pathology. Chemotherapy should be well tolerated.The subjects have the willing to undertake auto-HSCT after they have been in complete or partial remission or a salvage auto-HSCT when the disease progresses or the treatment fails;
2. Aged 15~65 years old;
3. ECOG 0~2 degree;
4. All the patients should be free of organ dysfunction and blood test,hepar,renal and cardiac function are basiclly normal;
5. All the patients should have no allergic reaction to amifostine.</inclusion_criteria>
      <agemin>15</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. The patients who receive treatment with other similar agents resently;
2. Pregnant or lactating;
3. Severe hypocalcemia (serum Calcimu&lt;2mmol/L);
4. Severe heart disease,including recorded congestive heart failure, high risk and uncontrolled arrhythmias, drug-dependent angina, confirmed heart valvular diseases,severe heart attack and resistant hypertension;
5. Severe hepar and renal dysfunction.(ALT&gt;8 times the upper limit of normal range,Ccr&lt;20ml/min);
6. Severe neurological diseases,mental disease and endocrine disease;
7. A history of substance abuse;
8. Have inttended other pharmaceutical experiments within 3 monthes;
9. The patients the investigater assess inappropiate to attend the study.(ex.: Those who can't tolerate the side-effects).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood regular test;Biochemistry indexes;Counts of stem cells;Estate evaluation;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-funding</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-08-29</approval_date>
        <contact_name>Yinghao Sha</contact_name>
        <contact_address>168 Yan'an Road West, Jing'an District, Shanghai, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>